ACIP Support Of FDA-Approved Prevnar 13 Creates Prospect For Larger Market
In a long-awaited move, the FDA approved on Feb. 23 Pfizer's Prevnar 13 vaccine for pneumococcal disease in children 5 years of age and younger, a crucial step in the drug maker's ability to build out the vaccine franchise that was central to its acquisition last year of Wyeth
You may also be interested in...
Advisory committee might closely scrutinize the requested indication for the 13-valent pneumococcal conjugate vaccine for adults age 50 and up; it is now indicated for children under six years old.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011